Breen EC, Boscardin WJ, Detels R, Jacobson LP, Smith MW, O'Brien SJ, Chmiel JS, Rinaldo CR, Lai S, Martinez-Maza O (2003) Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592 C...
The most common type of non-Hodgkin's lymphoma is called diffuse large B-cell lymphoma (DLBCL). One in three people with lymphoma have this type, and it mainly affects older adults. It’s a fast-growing cancer that can start in your lymph nodes or related organs like your thymus, spleen...
doi:10.1111/apt.15132Background Chronic hepatitis B has been linked to lymphoma with contradictory results.WileyAlimentary Pharmacology & Therapeutics
In this study we investigated the applicability of 99mTc-labeled CD19 monoclonal antibody (mAb) for tumor imaging in patients with B cell non-Hodgki
Targeted inhibitors of B-cell receptor signaling have emerged as the most promising therapeutic options against non-Hodgkin's lymphoma. The inhibitor agent... L Ysebaert,AS Michallet - 《Current Opinion in Oncology》 被引量: 13发表: 2014年 Bruton's tyrosine kinase inhibitors in B-cell non-Hod...
Non-Hodgkin's lymphoma (NHL) occurs with the malignant (cancerous) growth of B or T cells. Although both types can develop into lymphomas, B-cell lymphomas are much more common, accounting for 85% of all cases of NHL compared to T-cell lymphomas, which account for 15% of all cases of...
Off Label Use: We are describing a phase II study of the use of 90Y-Ibritumomab Tiuxetan for treatment of diffuse large B-cell lymphoma. Current FDA approved use of 90Y-Ibritumomab Tiuxetan includes relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL) or prev...
Is there a benefit to adding rituximab to CHOP in the overall survival of patients with B-cell non-Hodgkin’s lymphoma in a developing country? Hematology Vol 17, No 4Is there a benefit to adding rituximab to CHOP in the overall survival of patients with B-cell non-Hodgkin’s lymphoma in...
There is a difference between Hodgkin's lymphoma and non-Hodgkin's lymphoma, but there is some common confusion over the two diseases. Learn more about the differences between Hodgkin's lymphoma and non-Hodgkin's lymphoma, discover what lymphoid tissue is, and explore lymphoma and its effects ...
The optimal choice of salvage therapy for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or Hodgkin lymphoma (HL) remains unknown. Based on promising results of phase II trials, the preferred salvage regimen in British Columbia since 2002 has been the out-patient regimen,...